Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

COVID-19 and Vitamin D: Length of Hospital Stay and Mortality

3. februar 2022 oppdatert av: Sevan ÇETİN ÖZBEK, Yuksek Ihtisas University

Vitamin D Level: Reflections of a Public Health Issue in the COVID-19 Pandemic. Does it Affect Mortality and Length of Hospital Stay?

The lack of a pharmacological treatment in the COVID-19 pandemic has pushed scientists to search for this issue. Maintaining optimal health is parallel to adequate and balanced nutrition. In this context, can the protective properties of vitamin D play an important role in this pandemic? brought with it the thought. In this study, it was aimed to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease.

Studieoversikt

Status

Fullført

Forhold

Detaljert beskrivelse

This research was conducted to examine the effect of vitamin D on mortality and hospital stay in COVID-19 disease. For this, the approval of the Ministry of Health and then the ethics committee was obtained. For this reason, patients with positive PCR tests and hospitalized patients with vitamin D levels in their biochemistry were included in the study.

The data of the patients were obtained from the medical records. Information such as age, gender, comorbidities, length of hospital stay, vitamin D level were included in the study. According to the statistical analyzes obtained from these data, it has been shown that vitamin D level has no effect on mortality and hospital stay in COVID-19 disease.

Studietype

Observasjonsmessig

Registrering (Faktiske)

168

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Tyrkia
- - Ankara, Tyrkia, 06800
    - Republic of Turkey Ministry of Health Ankara City Hospitals Neurology-Orthopedics Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Sannsynlighetsprøve

Studiepopulasjon

Adult patients with positive COVID-19 PCR (Polymerase Chain Reaction) test and vitamin D level in biochemical parameters, who applied to Ankara City Hospital Neurology-Orthopedics Hospital between 01 August and 31 October 2020.

Beskrivelse

Inclusion Criteria:

COVID-19 PCR (Polymerase Chain Reaction) test positive
Vitamin D level in biochemical parameters
Adult patients hospitalized for COVID-19

Exclusion Criteria:

-Patients using drugs that may affect vitamin D absorption, such as corticosteroids, cholesterol-lowering agents, phenobarbital and phenytoin-containing agents

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Antall grupper / kohorter

Kohorter og intervensjoner

Gruppe / Kohort
Patients with COVID-19 + with vitamin D levels Patients with COVID-19 + and vitamin D levels were included in the study retrospectively. Vitamin D level was categorized into 3 groups as inadequacy, deficiency and normal from medical records. No intervention was made.

Hva måler studien?

Primære resultatmål

Resultatmål	Tiltaksbeskrivelse	Tidsramme
Level of Vitamin D Tidsramme: 1 month later	Vitamin D levels of patients with a diagnosis of COVID-10. These results were categorized at the level of deficiency/insufficiency/normal.	1 month later
Relationship between vitamin D level and mortality Tidsramme: 1 month later	Relationship between survival and death by categorized vitamin D level.	1 month later
Relationship between vitamin D level and hospital stay Tidsramme: 1 month later	Length of hospital stay by categorized vitamin D level.	1 month later

Sekundære resultatmål

Resultatmål	Tiltaksbeskrivelse	Tidsramme
Effects of additional diseases (Diabetes mellitus, hypertension, etc.) on hospital stay and mortality Tidsramme: 1 month later.	Evaluation of the impact of comorbidities on survival during COVID-19 disease.	1 month later.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Yuksek Ihtisas University

Samarbeidspartnere

Ankara City Hospital Bilkent

Etterforskere

Studieleder: Levent Öztürk, MD, Republic of Turkey Ministry of Health Ankara City Hospitals Neurology-Orthopedics Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

21. august 2021

Primær fullføring (Faktiske)

9. november 2021

Studiet fullført (Faktiske)

16. november 2021

Datoer for studieregistrering

Først innsendt

2. februar 2022

Først innsendt som oppfylte QC-kriteriene